Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
about
Structural and Functional Properties of the Hepatitis C Virus p7 ViroporinVpu Protein: The Viroporin Encoded by HIV-1Viral Membrane Channels: Role and Function in the Virus Life CycleThe HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonismTopology and biological function of enterovirus non-structural protein 2B as a member of the viroporin familyModels for predicting effective HIV chemoprevention in womenBacteria-based analysis of HIV-1 Vpu channel activity.Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors.Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.The minimalist architectures of viroporins and their therapeutic implications.Tetherin and its viral antagonists.The antiviral compound BIT225 inhibits HIV-1 replication in myeloid dendritic cells.CD4-gp120 interaction interface - a gateway for HIV-1 infection in human: molecular network, modeling and docking studies.Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replicationNovel Acylguanidine-Based Inhibitor of HIV-1.Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride."Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?Ion Channel Activity of Vpu Proteins Is Conserved throughout Evolution of HIV-1 and SIV.A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection.The Molecular Switch of Telomere Phages: High Binding Specificity of the PY54 Cro Lytic Repressor to a Single Operator Site.
P2860
Q26799884-7AC66005-5CDF-4DA9-923D-4DBD2D825C50Q26801489-2E22D9BE-B719-4F59-89BA-9CF84C965E37Q27000898-2F3C5687-1516-4EFE-9ECE-08F2B3751B9DQ28742774-880E01F2-2BB2-4C2C-B728-0DE4F90442E0Q34136039-320B414E-DA31-481C-ADAD-FBAF9EE55D3CQ35102285-FFF12F4F-E166-4A18-AB43-F15745FF9720Q35291655-6292A825-E089-4F36-84E0-72C8D453DF2BQ35591789-FC9D9271-D85A-40D9-BDAF-15B9A7133E4CQ35778972-05C9A039-F0E3-4EE4-A091-29E20B38BB91Q36376142-EF96EB03-9C82-49F8-9C83-6EBE1159EDADQ37619619-562EAF3E-AA69-40F7-974E-BD7792C47C3BQ37827428-AD55C9C8-451D-430C-B6FD-976457EC7964Q38281910-120795F8-4DBB-49C0-A3DB-C981DD01D1C9Q38377965-6F0E8D04-CD2B-40F0-90E3-66FD251DE229Q38739273-FD31FC76-0383-41D2-9A73-474D90099AFBQ38752518-AEBC418A-9852-44A1-8B7B-20DCF82F96AAQ38770144-4705B63C-74C5-41F2-85D1-303045E9C310Q39077941-5B0208CD-8956-4E46-BD70-AA23F7A36F31Q40042729-0F329A79-6073-4916-88D8-B47A5926E21CQ40889648-8E7E8D27-3BEA-4131-8F96-5A220BEE3446Q41504905-A8FAB2EE-8190-47F6-A7D3-89DA1B23F404
P2860
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antiviral efficacy of the nove ...... elease from human macrophages.
@ast
Antiviral efficacy of the nove ...... elease from human macrophages.
@en
type
label
Antiviral efficacy of the nove ...... elease from human macrophages.
@ast
Antiviral efficacy of the nove ...... elease from human macrophages.
@en
prefLabel
Antiviral efficacy of the nove ...... elease from human macrophages.
@ast
Antiviral efficacy of the nove ...... elease from human macrophages.
@en
P2093
P2860
P356
P1476
Antiviral efficacy of the nove ...... release from human macrophages
@en
P2093
Carolyn Luscombe
Gary Ewart
Michelle Miller
P2860
P304
P356
10.1128/AAC.01308-09
P407
P577
2009-12-07T00:00:00Z